hydroxychloroquine has been researched along with Day Blindness in 40 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)." | 7.67 | Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989) |
| ", chloroquine and hydroxychloroquine, in pregnant patients with lupus who continued antimalarial drugs throughout pregnancy." | 5.08 | Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. ( Parke, A; West, B, 1996) |
| "Chloroquine and hydroxychloroquine effectively suppress rheumatoid arthritis with a superior benefit to risk ratio." | 5.05 | Antimalarial drugs for rheumatoid arthritis. ( Mackenzie, AH, 1983) |
| "To report a rare case of cystoid macular edema (CME) as a presentation of acute hydroxychloroquine-related retinal toxicity." | 4.31 | Unusual Presentation of Acute Hydroxychloroquine Retinopathy. ( Cheng, CK; Lian, YY; Ma, YC, 2023) |
| "To assess the sensitivity and specificity of microperimetry as a screening test to detecting hydroxychloroquine retinopathy." | 3.91 | MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. ( Iftikhar, M; Kaur, R; Kherani, S; Nefalar, A; Petri, M; Rashid, I; Scholl, HPN; Schönbach, E; Shah, SM; Usmani, B, 2019) |
| "Hydroxychloroquine therapy during pregnancy is thought to be safe for foetuses." | 3.75 | Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. ( Flores-Guevara, R; Gold, F; Renaud, C; Renault, F; Richard, P; Vermersch, AI, 2009) |
| "We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)." | 3.67 | Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989) |
| "Hydroxychloroquine (HCQ) is an anti-inflammatory drug in widespread use for the treatment of systemic auto-immune diseases." | 1.72 | MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG. ( Gupta, A; Habib, F; Huang, H; Wright, T, 2022) |
| "Two patients with dermatological conditions developed retinal toxicity after treatment with hydroxychloroquine that exceeded dosing recommendations." | 1.48 | Hydroxychloroquine retinal toxicity in two patients with dermatological conditions. ( Baker, C; Kowalski, T; Mack, HG, 2018) |
| "Hydroxychloroquine is an oral antimalarial medication commonly used off-label for a variety of rheumatological conditions, including systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and dermatomyositis." | 1.46 | Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy. ( Chansky, PB; Werth, VP, 2017) |
| " Careful screening with multiple tests can detect toxic damage before prominent loss of the outer nuclear layer." | 1.38 | Comparison of screening procedures in hydroxychloroquine toxicity. ( Marmor, MF, 2012) |
| " In patients in whom the daily dosage of hydroxychloroquine could be estimated (12 of 13), when using actual body weight, 8 were taking 6." | 1.37 | Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. ( Francis, PJ; Michaelides, M; Stover, NB; Weleber, RG, 2011) |
| " All patients received the medication for at least one year and most were treated with a daily dosage of 400 mg." | 1.26 | Hydroxychloroquine. Seven-year experience. ( Krohel, G; Rynes, RI; Tobin, DR, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.50) | 18.7374 |
| 1990's | 2 (5.00) | 18.2507 |
| 2000's | 7 (17.50) | 29.6817 |
| 2010's | 20 (50.00) | 24.3611 |
| 2020's | 6 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Habib, F | 1 |
| Huang, H | 1 |
| Gupta, A | 1 |
| Wright, T | 1 |
| Lian, YY | 1 |
| Ma, YC | 1 |
| Cheng, CK | 1 |
| Kim, KE | 1 |
| Ryu, SJ | 1 |
| Kim, YH | 1 |
| Seo, Y | 1 |
| Ahn, SJ | 2 |
| Zone-Abid, I | 1 |
| Maaloul, K | 1 |
| Halouani, S | 1 |
| Frikha, F | 1 |
| Marzouk, S | 1 |
| Bahloul, Z | 1 |
| Trigui, A | 1 |
| Joung, J | 1 |
| Lee, BR | 1 |
| Rosenbaum, JT | 1 |
| Costenbader, KH | 1 |
| Desmarais, J | 1 |
| Ginzler, EM | 1 |
| Fett, N | 1 |
| Goodman, SM | 1 |
| O'Dell, JR | 1 |
| Schmajuk, G | 1 |
| Werth, VP | 2 |
| Melles, RB | 3 |
| Marmor, MF | 5 |
| Chansky, PB | 1 |
| Guiot, A | 1 |
| Couturier, M | 1 |
| Tebib, JG | 1 |
| Abouaf, L | 1 |
| Coury, F | 1 |
| Kowalski, T | 1 |
| Baker, C | 1 |
| Mack, HG | 1 |
| Rayess, N | 1 |
| Patel, VR | 1 |
| Iftikhar, M | 1 |
| Kaur, R | 1 |
| Nefalar, A | 1 |
| Usmani, B | 1 |
| Kherani, S | 1 |
| Rashid, I | 1 |
| Schönbach, E | 1 |
| Petri, M | 1 |
| Scholl, HPN | 1 |
| Shah, SM | 1 |
| Yeshurun, A | 1 |
| Bergman, R | 1 |
| Bathish, N | 1 |
| Khamaysi, Z | 1 |
| Pham, BH | 1 |
| Garrity, ST | 1 |
| Jung, JY | 1 |
| Zambrowski, O | 1 |
| Pichi, F | 1 |
| Su, D | 1 |
| Arya, M | 1 |
| Waheed, NK | 1 |
| Duker, JS | 1 |
| Chetrit, Y | 1 |
| Miserocchi, E | 1 |
| Giuffrè, C | 1 |
| Kaden, TR | 1 |
| Querques, G | 1 |
| Souied, EH | 1 |
| Freund, KB | 2 |
| Sarraf, D | 1 |
| Phillips, BN | 1 |
| Chun, DW | 1 |
| Tsang, AC | 1 |
| Ahmadi Pirshahid, S | 1 |
| Virgili, G | 1 |
| Gottlieb, CC | 1 |
| Hamilton, J | 1 |
| Coupland, SG | 1 |
| Bhavsar, KV | 1 |
| Mukkamala, LK | 1 |
| Modi, YS | 1 |
| Singh, RP | 1 |
| Fine, HF | 1 |
| Kellner, U | 1 |
| Lai, TY | 1 |
| Mieler, WF | 1 |
| Iselin, KC | 1 |
| Marti, P | 1 |
| Pless, M | 1 |
| Vavvas, D | 1 |
| Huynh, N | 1 |
| Pasquale, L | 1 |
| Berson, EL | 1 |
| Chiffoleau, A | 1 |
| Guillet, A | 1 |
| Zanlonghi, X | 1 |
| Jolliet, P | 1 |
| Renault, F | 1 |
| Flores-Guevara, R | 1 |
| Renaud, C | 1 |
| Richard, P | 1 |
| Vermersch, AI | 1 |
| Gold, F | 1 |
| Ingster-Moati, I | 1 |
| Albuisson, E | 1 |
| Stepien, KE | 1 |
| Han, DP | 1 |
| Schell, J | 1 |
| Godara, P | 1 |
| Rha, J | 1 |
| Carroll, J | 1 |
| Michaelides, M | 1 |
| Stover, NB | 1 |
| Francis, PJ | 1 |
| Weleber, RG | 1 |
| Hickley, NM | 1 |
| Al-Maskari, A | 1 |
| McKibbin, M | 1 |
| Wozniacka, A | 1 |
| McCauliffe, DP | 1 |
| Elder, M | 1 |
| Rahman, AM | 1 |
| McLay, J | 1 |
| Pautler, SE | 1 |
| Bienfang, DC | 1 |
| Mackenzie, AH | 1 |
| Tobin, DR | 1 |
| Krohel, G | 1 |
| Rynes, RI | 1 |
| Feldmann, R | 1 |
| Salomon, D | 1 |
| Saurat, JH | 1 |
| Parke, A | 1 |
| West, B | 1 |
| Olson, NY | 1 |
| Lindsley, CB | 1 |
| Sammartino, JP | 1 |
| Soll, DB | 1 |
| Pinckers, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope[NCT04361318] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| A Multi-site, Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Standard of Care (SOC) Plus Famotidine vs SOC Plus Placebo for the Treatment of COVID-19 in Hospitalized Adults[NCT04370262] | Phase 3 | 233 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Posterior Segment Evaluation of Patients With Systemic Lupus Erythematosus Using Optical Coherence Tomography and Optical Coherence Tomography Angiography[NCT04866615] | 150 participants (Anticipated) | Observational | 2021-06-04 | Recruiting | |||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
3 reviews available for hydroxychloroquine and Day Blindness
| Article | Year |
|---|---|
Hydroxychloroquine and chloroquine retinopathy: a systematic review evaluating the multifocal electroretinogram as a screening test.
Topics: Antirheumatic Agents; Chloroquine; Electroretinography; Fluorescein Angiography; Humans; Hydroxychlo | 2015 |
Hydroxychloroquine: A Brief Review on Screening, Toxicity, and Progression.
Topics: Antimalarials; Antirheumatic Agents; Disease Progression; Humans; Hydroxychloroquine; Practice Guide | 2016 |
Optimal use of antimalarials in treating cutaneous lupus erythematosus.
Topics: Antimalarials; Chloroquine; Drug Interactions; Humans; Hydroxychloroquine; Lupus Erythematosus, Cuta | 2005 |
2 trials available for hydroxychloroquine and Day Blindness
| Article | Year |
|---|---|
Antimalarial drugs for rheumatoid arthritis.
Topics: Amodiaquine; Antimalarials; Arthritis, Rheumatoid; Body Weight; Chloroquine; Clinical Trials as Topi | 1983 |
Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Topics: Antimalarials; Child, Preschool; Contraindications; Female; Fetus; Follow-Up Studies; Hearing Disord | 1996 |
35 other studies available for hydroxychloroquine and Day Blindness
| Article | Year |
|---|---|
MERCI: a machine learning approach to identifying hydroxychloroquine retinopathy using mfERG.
Topics: Antirheumatic Agents; Electroretinography; Humans; Hydroxychloroquine; Machine Learning; Quality of | 2022 |
Unusual Presentation of Acute Hydroxychloroquine Retinopathy.
Topics: Adult; Antirheumatic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fluorescein An | 2023 |
Visual field examinations using different strategies in Asian patients taking hydroxychloroquine.
Topics: Antirheumatic Agents; Electroretinography; Fluorescein Angiography; Humans; Hydroxychloroquine; Reti | 2022 |
Screening for toxic retinopathy due to antimalarial drugs in Tunisia.
Topics: Antimalarials; Cross-Sectional Studies; Humans; Hydroxychloroquine; Retinal Diseases; Tomography, Op | 2023 |
Evaluation of Hydroxychloroquine Retinopathy Using Ultra-Widefield Fundus Autofluorescence: Peripheral Findings in the Retinopathy.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Female; Fluorescein Angiography; Humans; Hydroxychl | 2020 |
Collaboration for the Management of Hydroxychloroquine.
Topics: Antirheumatic Agents; Disease Management; Humans; Hydroxychloroquine; Ophthalmology; Rheumatology; S | 2021 |
Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy.
Topics: Ataxia; Drug Overdose; Female; Humans; Hydroxychloroquine; Middle Aged; Paresthesia; Tinnitus; Visio | 2017 |
[Antimalarial drug retinopathy].
Topics: Adult; Antimalarials; Chloroquine; Electroretinography; Humans; Hydroxychloroquine; Lupus Erythemato | 2018 |
Hydroxychloroquine retinal toxicity in two patients with dermatological conditions.
Topics: Aged; Antimalarials; Female; Humans; Hydroxychloroquine; Lichen Planus; Lichen Sclerosus et Atrophic | 2018 |
Bilateral Severe Decreased Vision With Normal Examination Findings.
Topics: Adult; Antibiotics, Antineoplastic; Antirheumatic Agents; Autoimmune Diseases; Cataract; Cystic Fibr | 2018 |
MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study.
Topics: Adult; Aged; Antirheumatic Agents; Enzyme Inhibitors; Female; Fluorescein Angiography; Humans; Hydro | 2019 |
Hydroxychloroquine sulphate therapy of erosive oral lichen planus.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Exanthema; Female; Humans; Hydroxychloroquine; Hyperpigm | 2019 |
SEQUENTIAL CHANGES IN HYDROXYCHLOROQUINE RETINOPATHY UP TO 20 YEARS AFTER STOPPING THE DRUG: Implications for Mild Versus Severe Toxicity.
Topics: Antirheumatic Agents; Disease Progression; Enzyme Inhibitors; Female; Fluorescein Angiography; Fovea | 2019 |
Early hydroxychloroquine retinopathy: optical coherence tomography abnormalities preceding Humphrey visual field defects.
Topics: Adult; Aged; Antirheumatic Agents; Chronic Disease; Early Diagnosis; Electroretinography; Female; Hu | 2019 |
Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.
Topics: Aged; Antirheumatic Agents; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxychl | 2014 |
Hydroxychloroquine retinopathy after short-term therapy.
Topics: Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Middle Aged; Retinal Diseases; Vision Diso | 2014 |
Multimodal imaging in a severe case of hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Atrophy; Electroretinography; Female; Fluorescein Angiography; Humans; Hydroxy | 2015 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Topics: Academies and Institutes; Adult; Antirheumatic Agents; Asian People; Chloroquine; Electroretinograph | 2016 |
Hydroxychloroquine-Induced Retinal Toxicity.
Topics: Antirheumatic Agents; Diagnosis, Differential; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 2016 |
Progressive hydroxychloroquine toxicity mimicking low-tension glaucoma after discontinuation of the drug.
Topics: Aged; Atrophy; Diagnosis, Differential; Disease Progression; Drug Administration Schedule; Electrore | 2010 |
[Antimalarial's retinopaty remains a current threat].
Topics: Antimalarials; Arthritis, Rheumatoid; Chloroquine; Cohort Studies; Dose-Response Relationship, Drug; | 2009 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Antirheumatic Agents; Connective Tissue Diseases; Electroretinography; Evoked Potentials, Visual; Fe | 2009 |
Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero.
Topics: Electroretinography; Evoked Potentials, Visual; Female; Humans; Hydroxychloroquine; Infant; Infant, | 2010 |
Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss.
Topics: Antirheumatic Agents; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lupus Erythematos | 2009 |
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Chloroquine; Disease Progression; Drug Therapy | 2011 |
Chloroquine and hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Chloroquine; Female; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Vis | 2011 |
Comparison of screening procedures in hydroxychloroquine toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Diagnostic Techniques, Ophthalmological; E | 2012 |
Early paracentral visual field loss in patients taking hydroxychloroquine.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Antirheumatic Agents; Child; Female; H | 2006 |
Hydroxychloroquine dosages should be calculated using lean body mass.
Topics: Antirheumatic Agents; Body Mass Index; Humans; Hydroxychloroquine; Retina; Vision Disorders; Visual | 2007 |
Screening for hydroxychloroquine toxicity.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Kidney Function Tests; Liver Function Tests; Retin | 2007 |
Hydroxychloroquine. Seven-year experience.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Middle Aged; Retinal Disea | 1982 |
The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Topics: Adult; Aged; Chloroquine; Drug Combinations; Drug Tolerance; Female; Humans; Hydroxychloroquine; Lup | 1994 |
Adjunctive use of hydroxychloroquine in childhood dermatomyositis.
Topics: Adolescent; Antineoplastic Agents; Child; Dermatomyositis; Drug Therapy, Combination; Female; Humans | 1989 |
Ocular toxicity of systemic drugs.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Chloroquine; Contraceptives, Oral; Digitalis; Eye Di | 1985 |
[Eye disorders caused by chloroquine and hydroxychloroquine].
Topics: Adult; Chloroquine; Color Perception Tests; Electrooculography; Eye Manifestations; Female; Humans; | 1970 |